BioCentury
ARTICLE | Company News

Altea, KAI deal

January 25, 2010 8:00 AM UTC

The companies will use Altea's PassPort Transdermal Delivery System to co-develop three undisclosed protein kinase C (PKC) inhibitors from KAI to treat pain, hyperparathyroidism and a potential third...